Clinical Trials List
2017-05-10 - 2025-12-31
Phase III
Terminated3
ICD-10C22.0
Liver cell carcinoma
ICD-10C22
Malignant neoplasm of liver and intrahepatic bile ducts
ICD-9155.0
Malignant neoplasm of liver, primary
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- Hung-Wei Wang Digestive System Department
- Cheng-Yuan Peng Digestive System Department
- Hung-Yao Chen Digestive System Department
- 蘇文邦 Digestive System Department
- Po-Heng Chuang Digestive System Department
- 陳昇弘 Digestive System Department
- Wei-Fan Hsu Digestive System Department
- Hsueh-Chou Lai Digestive System Department
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 吳毅晉 Digestive System Department
- Liu Yi-Sheng Division of Radiology
- 邱彥程 Digestive System Department
- Nai-Jung Chiang Division of Hematology & Oncology
- Pin-Nan Cheng Digestive System Department
- 簡世杰 Digestive System Department
- Yih-Jyh Lin Division of General Surgery
- Chiu Hung Chiu Digestive System Department
The Actual Total Number of Participants Enrolled
0 Terminated
Audit
None
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
Audit
None
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
16 participants
-
Global
450 participants
